Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $26,399.86 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Mark Jeffrey Delong sold 1,334 shares of the stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $19.79, for a total value of $26,399.86. Following the sale, the insider owned 81,724 shares in the company, valued at approximately $1,617,317.96. This trade represents a 1.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Mark Jeffrey Delong also recently made the following trade(s):

• On Thursday, January 22nd, Mark Jeffrey Delong sold 3,371 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $21.77, for a total value of $73,386.67.
• On Tuesday, January 13th, Mark Jeffrey Delong sold 1,780 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $22.19, for a total value of $39,498.20.

Apellis Pharmaceuticals Trading Down 1.1%

Shares of APLS stock opened at $21.76 on Friday. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of 70.18 and a beta of 0.31. The company has a current ratio of 3.54, a quick ratio of 3.10 and a debt-to-equity ratio of 0.90. The firm has a 50-day moving average price of $23.02 and a 200 day moving average price of $23.52. Apellis Pharmaceuticals, Inc. has a twelve month low of $16.10 and a twelve month high of $30.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Thursday, October 30th. The company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.64. The business had revenue of $458.58 million during the quarter, compared to the consensus estimate of $364.58 million. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The company’s quarterly revenue was up 133.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.46) earnings per share. Research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on APLS shares. HC Wainwright decreased their price objective on Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Wells Fargo & Company decreased their price target on Apellis Pharmaceuticals from $29.00 to $26.00 and set an “overweight” rating on the stock in a research note on Tuesday. Stifel Nicolaus dropped their price objective on shares of Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Mizuho decreased their target price on shares of Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. Finally, Wall Street Zen raised shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Twelve research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.53.

Trending Headlines about Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
• Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re‑rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near‑term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Marshall Wace LLP increased its position in shares of Apellis Pharmaceuticals by 11,373.8% in the second quarter. Marshall Wace LLP now owns 2,704,837 shares of the company’s stock worth $46,821,000 after acquiring an additional 2,681,263 shares in the last quarter. Norges Bank purchased a new position in Apellis Pharmaceuticals in the second quarter valued at about $40,977,000. AQR Capital Management LLC lifted its stake in shares of Apellis Pharmaceuticals by 46.6% during the second quarter. AQR Capital Management LLC now owns 5,976,414 shares of the company’s stock worth $103,452,000 after purchasing an additional 1,898,995 shares in the last quarter. Polar Capital Holdings Plc lifted its stake in shares of Apellis Pharmaceuticals by 96.0% during the third quarter. Polar Capital Holdings Plc now owns 2,650,230 shares of the company’s stock worth $59,975,000 after purchasing an additional 1,298,055 shares in the last quarter. Finally, Amundi boosted its position in shares of Apellis Pharmaceuticals by 386.7% in the second quarter. Amundi now owns 1,604,105 shares of the company’s stock worth $28,585,000 after buying an additional 1,274,523 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.